Expression regulation of Bnip3 and its relationship with tumors

doi:10.3760/cma.j.issn.1673422X.2013.11.002

Abstract

Abstract: Bnip3, a kind of mitochondrion apoptosis gene, belongs to the Bcl2 gene family and BH3only subfamily. It is one of the downstream response factors of hypoxia inducible factor (HIF). Bnip3 can induce cell apoptosis and autophagy under the oxygen deficit condition. Many studies show that Bnip3 is closely related to the occurrence, development and treatment of tumors. Molecular targeting treatment aimed at Bnip3 combined with chemoradiotherapy has preferable application foreground in tumor therapy.

Key words: Gene expression regulation, Neoplasms, Bnip3 gene

WANG Yan, LI Zhi-Ping. Expression regulation of Bnip3 and its relationship with tumors[J]. Journal of International Oncology, 2013, 40(11): 807-810.

References

［1］ Chen Y, Lewis W, Diwan A. et al. Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. Proc Natl Acad Sci USA, 2010, 107(20):9035-9042. ［2］ Kubli DA, Ycaza JE, Gustafsson AB. Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak. Biochem J, 2007,405(3):407-415. ［3］ Rajaie AN, Mallikarjuna RM, Rajeev D, et al. Hypoxiainduced overexpression of BNIP3 is not dependent on HIF-1α in mouse hepatocytes. Shock, 2011, 36(2): 196-202. ［4］ Qi YM, Tian XX, Liu J, et al. Bnip3 and AIF cooperate to induce apoptosis and cavitation during epithelial morphogenesis. J Cell Biol, 2012, 198(1):103-114. ［5］ Yurkova N, Shaw J, Blackie K, et al. The cell cycle factor E2F-1 activates Bnip3 and the intrinsic death pathway in ventricular myocytes. Circ Res, 2008, 102(4):472-479. ［6］ Shaw J, Yurkova N, Zhang T, et al. Antagonism of E2F-1 regulated Bnip3 transcription by NF-kappa B is essential for basal cells survival. Proc Natl Acad Sci USA, 2008, 105 (52) :20734-20739. ［7］ Gang H, Dhingra R, Wang Y, et al. Epigenetic regulation of E2F-1dependent Bnip3 transcription and cell death by nuclear factor-κB and histone deacetylase-1. Pediatr Cardiol, 2011,32(3):263-266. ［8］ Zeng X, Kinsella TJ. BNIP3 is essential for mediating 6thioguanineand 5fluorouracilinduced autophagy following DNA mismatch repair processing. Cell Res, 2010,20(6): 665-675. ［9］ Feng X, Liu X, Zhang W, et al. p53 directly suppresses BNIP3 expression to protect against hypoxiainduced cell death. EMBO J, 2011,30(16): 3397-3415. ［10］ Kalas W, Swiderek E, Rapak A， et al. Hras upregulates expression of BNIP3. Anticancer Res, 2011,31(9):2869-2875. ［11］ Wu SY, Lan SH, Cheng DE, et al. Rasrelated tumorigenesis is suppressed by BNIP3mediated autophagy through inhibition of cell proliferation. Neoplasia, 2011,13(12): 1171-1182. ［12］ Chen XQ, Gong J, Zeng H, et al. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res, 2010,70(7):2728-2738. ［13］ Diwan A, Krenz M, Syed FM, et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest, 2007, 117(10):2825-2833. ［14］ Kubli DA, Quinsay MN, Huang C， et al. Bnip3 functions as a mitochondrial sensor of oxidative stress during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol, 2008,295（5）:H2025-H2031. ［15］ Graham RM, Thompson JW, Wei J, et al. Regulation of bnip3 death pathways by calcium, phosphorylation, and hypoxiareoxygenation. Antioxid Redox Signal, 2007,9(9):1309-1316. ［16］ Mellor HR, Rouschop KM, Wigfield SM， et al. Synchronised phosphorylation of BNIP3, Bcl2, and BclxL in response to microtubuleactive drugs is JNKindependent and requires a mitotic kinase. Biochem Pharmacol ,2010,79（11）:1562-1572. ［17］ Jurasz P, Yurkova N, Kirshenbaum L, et al. VEGF masks BNIP3mediated apoptosis of hypoxic endothelial cells.Angiogenesis, 2011,14(2): 199-207. ［18］ Kim JY, Kim YJ, Lee S， et al. BNip3 is a mediator of TNFinduced necrotic cell death. Apoptosis, 2011,16(2): 114-126. ［19］ Song ZC，Zhou W, Shu R, et al. Hypoxia induces apoptosis and autophagic cell death in human periodontal ligament cells through HIF1α pathway. Cell Proliferation, 2012,45(3): 239-248. ［20］ Hiraki M, Kitajima Y, Nakafusa Y, et al. CpG island methylation of BNIP3 predicts resistance against S1/CPT11 combined therapy in colorectal cancer patients. Oncol Rep, 2010, 23(1):191-197. ［21］付涛, 安平, 李春穴, 等. BNIP3 基因甲基化与早期结直肠癌患者临床病理特征的关系. 中华普外科手术学杂志(电子版), 2012, 6(4):423-427. ［22］ Tang H, Liu YJ, Liu M, et al. Establishment and gene analysis of an oxaliplatinresistant colon cancer cell line THC8307/LOHP. Anticancer Drugs, 2007, 18(6):633-639. ［23］ Deng Q, Li ZP, Huang CM, et al. Effect and mechanism of DNMT inhibitor on the reversal of multidrug resistance in human colon cancer cell line sw620/LOHP. Sichuan Da Xue Xue Bao Yi Xue Ban, 2010, 41(6):975-979. ［24］ Wang Z, Huang C, Zeng J, et al. Effects of the proapoptotic regulator Bcl2/adenovirus EIB 19kDainteracting protein 3 on the chemosensitivity of human colon cancer cell lines. Oncol Lett， 2012， 4(6): 1195-1202. ［25］ Erkan M, Kleeff J, Esposito I, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene, 2005, 24(27): 4421-4432. ［26］ Ishida M, Sunamura M, Furukawa T, et al. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis. World J Gastroenterol, 2007, 13(34): 4593-4597. ［27］ Hong SM, Omura N, Vincent A， et al. Genomewide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res, 2012,18(24):700-712. ［28］ Sugita H, Iida S, Inokuchi M, et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep, 2011,25（2）:513-518. ［29］李能莲，张煦，樊平，等. BNIP3在胃癌中的表达及意义. 兰州大学学报（医学版）， 2007,33（1）：40-42. ［30］ Hiraki M, Kitajima Y, Koga Y, et al. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients.Ann Surg Oncol, 2011,18（10）:3013-3019. ［31］王银玲，王亿龙，王齐晖, 等. 腹腔冲洗液BNIP3基因甲基化与胃癌患者腹膜微转移及疾病的相关性研究. 中国医科大学学报， 2012，41（10）：934-936. ［32］ Wang Z, Huang CM, Deng Q, et al. Effects of the proapoptotic regulator Bcl2/adenovirus EIB 19 kDainteracting protein 3 on radiosensitivity of cervical cancer. Cancer Biother Radiopharm, 2011,26(3):279-286. ［33］ Tan EY, Campo L, Han C, et al. BNIP3 as a progression marker in primary human breast cancer:opposing functions in in situ versus invasive cancer. Clinl Cancer Res, 2007, 13(2 Pt1): 467-474. ［34］ Naushad SM, Prayaga A, Digumarti RR, et al. Bcl2/adenovirus E1B 19 kDainteracting protein 3 (BNIP3) expression is epigenetically regulated by onecarbon metabolism in invasive duct cell carcinoma of breast. Mol Cell Biochem, 2012,361(1-2):189-195. ［35］ Yoo NJ, Kim MS, Park SW, et al. Expression analysis of caspase6, caspase9 and BNIP3 in prostate cancer. Tumori, 2010,96(1):138-142.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.